Stock Analysts’ New Coverage for October 1st (CVEO, ELVN, FBIZ, FRPT, KURA, NMG, NPK, QCRH, STBA, SYRE)

Stock Analysts’ new coverage for Thursday, October 1st:

Northland Securities began coverage on shares of Civeo (NYSE:CVEO). They issued an outperform rating and a $42.00 price target on the stock.

JPMorgan Chase & Co. started coverage on shares of Enliven Therapeutics (NASDAQ:ELVN). They issued an overweight rating and a $75.00 price target on the stock.

Raymond James Financial, Inc. initiated coverage on shares of First Business Financial Services (NASDAQ:FBIZ). They issued an outperform rating and a $75.00 price target on the stock.

Needham & Company LLC assumed coverage on shares of Freshpet (NASDAQ:FRPT). They issued a hold rating on the stock.

JPMorgan Chase & Co. started coverage on shares of Kura Oncology (NASDAQ:KURA). The firm issued an overweight rating and a $30.00 target price on the stock.

Freedom Broker started coverage on shares of Nouveau Monde Graphite (NYSE:NMG). They issued a hold rating and a $1.48 target price on the stock.

Freedom Broker began coverage on shares of National Presto Industries (NYSE:NPK). They issued a hold rating and a $162.00 price target on the stock.

Raymond James Financial, Inc. started coverage on shares of QCR (NASDAQ:QCRH). The firm issued an outperform rating and a $110.00 price target on the stock.

Raymond James Financial, Inc. began coverage on shares of S&T Bancorp (NASDAQ:STBA). Raymond James Financial, Inc. issued a market perform rating on the stock.

JPMorgan Chase & Co. started coverage on shares of Spyre Therapeutics (NASDAQ:SYRE). JPMorgan Chase & Co. issued an overweight rating and a $110.00 target price on the stock.

TD Cowen initiated coverage on shares of Teva Pharmaceutical Industries (NYSE:TEVA). TD Cowen issued a buy rating and a $55.00 target price on the stock.

Morgan Stanley began coverage on shares of Toll Brothers (NYSE:TOL). Morgan Stanley issued an overweight rating and a $159.00 price target on the stock.

LADENBURG THALM/SH SH started coverage on shares of WAVE Life Sciences (NASDAQ:WVE). They issued a buy rating and a $10.00 target price on the stock.